Life Sciences Patents Network Europe
The Bloomsbury Hotel, London-UK, 7th December 2016

Agenda

Time Name Session Type Description
Wednesday, December 7, 2016
8:00 AM - 9:00 AMMorning Coffee & RegistrationNETWORKING
Sponsored by:
9:00 AM - 9:05 AMChair's Opening RemarksPRESENTATION
Peter Scott, Group Publisher, LSIPR (Newton Media Group)
9:05 AM - 9:25 AMOpening AddressPRESENTATION
Nicola Dagg, Partner, Allen & Overy
9:25 AM - 9:45 AMAsian Patents Market Perspectives - Recent Developments in Pharma Patent Case Law in JapanPRESENTATION
  • The Ministry of Health, Labour, and Welfare's promotion of the use of generic drugs - "80% generic" era
  • Patent term extension
  • Doctrine of equivalents
Takanori Abe, Managing Partner, Abe & Partners 
9:45 AM - 10:05 AMNaga - Understanding South AsiaPRESENTATION
  • Naga is neither snake nor dragon
  • Where did our patent laws come from?
  • Where are they now?
  • Naga will help you navigate the rivers
Ian Mirandah, 2nd Generation, mirandah asia​
10:05 AM - 10:40 AMEU Patents Market Overview: Trends to Watch Out for 2017-2020PRESENTATION
  • European patent developments 
  • Clinical trials and public availability of data
  • Patentability key updates
Heli Pihlajamaa, Director Patent Law, European Patent Office
10:40 AM - 11:00 AMNetworking & Coffee BreakNETWORKING
Sponsored by:
11:00 AM - 11:40 AMSecond Medical Use Infringement in the EUPANEL DISCUSSION
  • Impact of generic firms' carve-outs (skinny labelling and the "blue box" concept) to avoid second medical use patents on brand name companies' clinical innovation / R&D in an era of intense budgetary constraints
  • What must generic manufacturers do prior to launching a product where a second medical use patent is still in force?
  • What are the lessons learned from Warner-Lambert v Sandoz?
  • What steps should second medical use patent owners take when confronted with suspected infringement?
  • How can remedies or damages be assessed in the event of infringement?
  • Are there any major points in the ruling that are still unclear/need to be worked out? If yes, what should parties do in response to achieve clarity?
Chair:
Marjan Noor, Partner, Allen & Overy
 
Panellists:
Fiona Bor, Head of Intellectual Property, Mereo BioPharma Group
 
Sven Bostyn, Chair of Expert Group - Patent Law in Biotechnology & Genetic Engineering, European Commission
11:40 AM - 12:20 PMThe Unitary Patent & Unified Patent Court (UPC) PRESENTATION
Streamlining patents' protection & litigation across Europe
 
  • UK – in or out after Brexit?
           + C1/09 from CJEU vs Gordon & Pascoe’s analysis
           + Court structure with CJEU as final appeal instance
           + Effect of UK decision:
           + EPI position
           + Timing of enter into force
  • SPC with a view to soft Brexit vs hard Brexit  / Can you obtain an SPC based on a non-nationalised patent? 
  • Harmonization of national law across member states (e.g. research exemption, clinical trials for originators)
  • Infringement and speed of action
  • Renewal fees – they probably need to renegotiated in view of UK’s (expected) exit
  • Exhaustion of patent rights if a product is marketed in UK
  • Translation/language regime
Co-Presenters:
Bernd Hunter, Head of Intellectual Property, MorphoSys AG
 
Bo Kalum, European Patent Attorney/ Senior Patent Specialist, Global Patents, H. Lundbeck A/S
12:20 PM - 12:45 PMThe Importance of Joint Patents and Regulatory StrategyPRESENTATION
Understanding & taking advantage of data exclusivity periods and patent term extensions
  • Data exclusivity periods v patent term extensions (SPCs and paediatric extensions): what are the main differences, and when and how should you use them?
  • The interface of patents and regulatory drug approval process and its effect on market entry
  • Recent case studies
Ray Cresswell, Former Vice President, Legal Counsel, GlaxoSmithKline
12:45 PM - 1:40 PMNetworking LunchNETWORKING 
1:40 PM - 1:45 PMInteractive Roundtable Discussions & Deep Dive DebatesROUNDTABLE
  • This session includes a series of open, interactive roundtables on key insurance disruptions
  • All discussions run concurrently for 40 minutes
  • After 40 minutes participants will rotate to a different roundtable, allowing a total of two rotations
  • The first rotation will run from 13:45 to 14:25, and the second rotation from 14:25 to 15:05
  • Please see below for details on all available roundtables.
PLEASE SELECT YOUR TWO ROUNDTABLE ROTATIONS FROM THE LIST BELOW. SEAT ALLOCATION IS STRICTLY ON A FIRST TO RESERVE BASIS.
1:45 PM - 2:25 PMRotation 1: Technology TransferROUNDTABLE
Accelerating technology development for early R&D commercialisation
 
Chair: 
Susanne Ahlberg, General Counsel, Genovis
1:45 PM - 2:25 PMRotation 1: Navigating the CRISPR Patent LandscapeROUNDTABLE
​Avoiding patenting issues in collaborative research
 
Co-chairs: 
Dr. Claire Irvine, Partner, HGF 

Rachel Fetches, Partner, HGF
1:45 PM - 2:25 PMRotation 1: Managing the Patent LifecycleROUNDTABLE
How to make the most of your portfolio
1:45 PM - 2:25 PMRotation 1: Patent ApplicationROUNDTABLE
Drafting & filing
 
Chair:
Heli Pihlajamaa, Director Patent Law, European Patent Office
1:45 PM - 2:25 PMRotation 1: Clinical Trials & Data ProtectionROUNDTABLE
What we need from them & how to run them
 
Chair:
Ashley Roughton, Barrister, Venner Shipley
1:45 PM - 2:25 PMRotation 1: Adjusting to the Post-Brexit WorldROUNDTABLE
Chair: 
Marc Doring, Partner, Allen & Overy
1:45 PM - 2:25 PMRotation 1: Mature Licensing StrategiesROUNDTABLE
Co-Chairs:
Thomas Kolzau, CEO, Enin
Ednaldo Silva, Founder & Director, RoyaltyStat
2:30 PM - 3:10 PMRotation 2: Adjusting to the Post-Brexit World ROUNDTABLE
Chair: 
Marc Doring, Partner, Allen & Overy
2:30 PM - 3:10 PMRotation 2: Clinical Trials & Data ProtectionROUNDTABLE
What we need from them & how to run them 
 
Chair:
Ashley Roughton, Barrister, Venner Shipley
2:30 PM - 3:10 PMRotation 2: Technology TransferROUNDTABLE
Accelerating technology development for early R&D commercialisation 
 
Chair: 
Susanne Ahlberg, General Counsel, Genovis
2:30 PM - 3:10 PMRotation 2: Patent ApplicationROUNDTABLE
Drafting & filing 
 
Chair:
Heli Pihlajamaa, Director Patent Law, European Patent Office
2:30 PM - 3:10 PMRotation 2: Mature Licensing Strategies ROUNDTABLE
Co-Chairs:
Thomas Kolzau, CEO, Enin
 
Ednaldo Silva, Founder & Director, RoyaltyStat
2:30 PM - 3:10 PMRotation 2: Navigating the CRISPR Patent LandscapeROUNDTABLE
Avoiding patenting issues In collaborative research
 
​Co Chairs: 
Dr. Claire Irvine, Partner, HGF & Rachel Fetches, Partner, HGF
 
Rachel Fetches, Partner, HGF
2:30 PM - 3:10 PMRotation 2: Managing the Patent LifecycleROUNDTABLE
How to make the most of your portfolio
3:10 PM - 3:35 PMInteractive Roundtables Round UpPRESENTATION
5 minute presentations on key findings and learnings from each roundtable discussion
Debate & Q&A
Presenters:
Heli Pihlajamaa, Director Patent Law, European Patent Office
Thomas Kolzau, CEO, Enin
Ednaldo Silva, Founder & Director, RoyaltyStat
Susanne Ahlberg, General Counsel, Genovis
Marc Doring, Partner, Allen & Overy
Claire Irvine, Partner, HGF
Rachel Fetches, Partner, HGF
3:35 PM - 3:50 PMCoffee Break & NetworkingNETWORKING
Sponsored by:
3:50 PM - 4:10 PMImpact of the Elections on the U.S. Patent LandscapePRESENTATION
U.S. IP implications in light of:
  • Potential renegotiation of trade deals
  • Make-up of the House of Representatives and Senate
  • Potential Supreme Court nominees
Sanya Sukduang, Partner, Finnegan                                        
4:10 PM - 4:50 PMConsolidation vs Innovation: M&A Effect on Patents and LicensingPANEL DISCUSSION
  • The role of patent portfolios in the decision to acquire a business 
  • How do companies assess whether it makes business sense to acquire a patent portfolio?
  • How do companies value patents? What types of patents are more valuable than others?
  • Managing patent portfolios post-M&A deal
  • Competition/ antitrust law considerations for mergers
Panellists:
Emma Bassinder, European Patent Counsel, Eli Lilly and Company 
 
Maria Nichol, Vice President, IP, Galapagos
 
Marion Rees, IP Director, Circassia
4:50 PM - 5:30 PMPatents & Next Generation 3D Printing and BioprintingPRESENTATION
3D printing and bioprinting latest advances and applications for life sciences
  • What are the key life science patent issues arising from 3D printing and bioprinting
  • Preparing for the future
Co-Presenters: 
Sarah Turner, Partner, Hogan Lovells
 
Stella Wong, Senior Associate, Hogan Lovells
5:30 PM - 5:35 PMChair’s Closing RemarksPRESENTATION
Event Chair:
Peter Scott, Group Publisher, LSIPR (Newton Media Group)
5:35 PM - 6:30 PMNetworking DrinksNETWORKING
Interested in getting involved?   
 
For speaking and sponsorship opportunities contact: 
Jamie Playford
Head of Events
Tel: +44 (0) 203 301 8211
Email: jplayford@newtonmedia.co.uk